These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 25511894)

  • 1. Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.
    Lleó A; Cavedo E; Parnetti L; Vanderstichele H; Herukka SK; Andreasen N; Ghidoni R; Lewczuk P; Jeromin A; Winblad B; Tsolaki M; Mroczko B; Visser PJ; Santana I; Svenningsson P; Blennow K; Aarsland D; Molinuevo JL; Zetterberg H; Mollenhauer B
    Nat Rev Neurol; 2015 Jan; 11(1):41-55. PubMed ID: 25511894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.
    Zimmermann M; Brockmann K
    J Parkinsons Dis; 2022; 12(s1):S183-S200. PubMed ID: 35661021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of CSF biomarkers in Alzheimer's disease clinical trials.
    Blennow K; Zetterberg H
    J Nutr Health Aging; 2009 Apr; 13(4):358-61. PubMed ID: 19300880
    [No Abstract]   [Full Text] [Related]  

  • 4. Seeking progress in disease modification in Parkinson disease.
    Lungu C; Cedarbaum JM; Dawson TM; Dorsey ER; Faraco C; Federoff HJ; Fiske B; Fox R; Goldfine AM; Kieburtz K; Macklin EA; Matthews H; Rafaloff G; Saunders-Pullman R; Schor NF; Schwarzschild MA; Sieber BA; Simuni T; Surmeier DJ; Tamiz A; Werner MH; Wright CB; Wyse R
    Parkinsonism Relat Disord; 2021 Sep; 90():134-141. PubMed ID: 34561166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A beginner's guide into curated analyses of open access datasets for biomarker discovery in neurodegeneration.
    Gomes Moreira D; Jan A
    Sci Data; 2023 Jul; 10(1):432. PubMed ID: 37414779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are we close to using Alzheimer blood biomarkers in clinical practice?
    Imbimbo BP; Lista S; Imbimbo C; Nisticò R
    Neural Regen Res; 2024 Dec; 19(12):2583-2585. PubMed ID: 38808992
    [No Abstract]   [Full Text] [Related]  

  • 7. Epigenetic scores of blood-based proteins as biomarkers of general cognitive function and brain health.
    Smith HM; Moodie JE; Monterrubio-Gómez K; Gadd DA; Hillary RF; Chybowska AD; McCartney DL; Campbell A; Redmond P; Page D; Taylor A; Corley J; Harris SE; Valdés Hernández M; Muñoz Maniega S; Bastin ME; Wardlaw JM; Deary IJ; Boardman JP; Mullin DS; Russ TC; Cox SR; Marioni RE
    Clin Epigenetics; 2024 Mar; 16(1):46. PubMed ID: 38528588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neural Computation-Based Methods for the Early Diagnosis and Prognosis of Alzheimer's Disease Not Using Neuroimaging Biomarkers: A Systematic Review.
    Cabrera-León Y; Báez PG; Fernández-López P; Suárez-Araujo CP
    J Alzheimers Dis; 2024; 98(3):793-823. PubMed ID: 38489188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal hippocampal subfields, CSF biomarkers, and cognition in patients with Parkinson disease.
    Erhardt E; Horner A; Shaff N; Wertz C; Nitschke S; Vakhtin A; Mayer A; Adair J; Knoefel J; Rosenberg G; Poston K; Suarez Cedeno G; Deligtisch A; Pirio Richardson S; Ryman S
    Clin Park Relat Disord; 2023; 9():100199. PubMed ID: 38107672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory Mechanisms in a Neurovascular Disease: Cerebral Cavernous Malformation.
    Li Y; Srinath A; Alcazar-Felix RJ; Hage S; Bindal A; Lightle R; Shenkar R; Shi C; Girard R; Awad IA
    Brain Sci; 2023 Sep; 13(9):. PubMed ID: 37759937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.
    Pereira JB; Kumar A; Hall S; Palmqvist S; Stomrud E; Bali D; Parchi P; Mattsson-Carlgren N; Janelidze S; Hansson O
    Nat Aging; 2023 Oct; 3(10):1201-1209. PubMed ID: 37723208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Proteins in Cerebrospinal Fluid and Application to Glioma Biomarker Identification.
    He K; Wang Y; Xie X; Shao D
    Molecules; 2023 Apr; 28(8):. PubMed ID: 37110850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer's disease.
    Mansilla A; Canyelles M; Ferrer R; Arranz J; Rodríguez-Baz Í; Zhu N; Rubio-Guerra S; El Bounasri S; Sánchez O; Torres S; Fortea J; Lleó A; Alcolea D; Tondo M
    Clin Chem Lab Med; 2023 Aug; 61(9):1580-1589. PubMed ID: 37083158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
    Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
    JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid alpha-synuclein, amyloid beta, total tau, and phosphorylated tau in tremor-dominant Parkinson's disease.
    Nabizadeh F; Sodeifian F; Kargar A
    Acta Neurol Belg; 2023 Aug; 123(4):1429-1437. PubMed ID: 37000407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemokines in patients with Alzheimer's disease: A meta-analysis.
    Wang H; Zong Y; Zhu L; Wang W; Han Y
    Front Aging Neurosci; 2023; 15():1047810. PubMed ID: 36967827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmunity and SARS-CoV-2 infection: Unraveling the link in neurological disorders.
    Latorre D
    Eur J Immunol; 2022 Oct; 52(10):1561-1571. PubMed ID: 35833748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.
    Scott GD; Arnold MR; Beach TG; Gibbons CH; Kanthasamy AG; Lebovitz RM; Lemstra AW; Shaw LM; Teunissen CE; Zetterberg H; Taylor AS; Graham TC; Boeve BF; Gomperts SN; Graff-Radford NR; Moussa C; Poston KL; Rosenthal LS; Sabbagh MN; Walsh RR; Weber MT; Armstrong MJ; Bang JA; Bozoki AC; Domoto-Reilly K; Duda JE; Fleisher JE; Galasko DR; Galvin JE; Goldman JG; Holden SK; Honig LS; Huddleston DE; Leverenz JB; Litvan I; Manning CA; Marder KS; Pantelyat AY; Pelak VS; Scharre DW; Sha SJ; Shill HA; Mari Z; Quinn JF; Irwin DJ
    Front Neurol; 2021; 12():805135. PubMed ID: 35173668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.
    Reyes-Leiva D; Dols-Icardo O; Sirisi S; Cortés-Vicente E; Turon-Sans J; de Luna N; Blesa R; Belbin O; Montal V; Alcolea D; Fortea J; Lleó A; Rojas-García R; Illán-Gala I
    Front Neurol; 2021; 12():750543. PubMed ID: 35115992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone.
    Delaby C; Estellés T; Zhu N; Arranz J; Barroeta I; Carmona-Iragui M; Illán-Gala I; Santos-Santos MÁ; Altuna M; Sala I; Sánchez-Saudinós MB; Videla L; Valldeneu S; Subirana A; Tondo M; Blanco-Vaca F; Lehmann S; Belbin O; Blesa R; Fortea J; Lleó A; Alcolea D
    Alzheimers Res Ther; 2022 Feb; 14(1):20. PubMed ID: 35105351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.